Literature DB >> 30662802

Overexpression of YEATS4 contributes to malignant outcomes in gastric carcinoma.

Jun Kiuchi1, Shuhei Komatsu1, Taisuke Imamura1, Keiji Nishibeppu1, Katsutoshi Shoda1, Tomohiro Arita1, Toshiyuki Kosuga1, Hirotaka Konishi1, Atsushi Shiozaki1, Takeshi Kubota1, Kazuma Okamoto1, Hitoshi Fujiwara1, Daisuke Ichikawa2, Hitoshi Tsuda3,4, Eigo Otsuji1.   

Abstract

YEATS domain containing 4 (YEATS4) has functions of chromatin modification and transcriptional regulation and is in a gene-amplified region (12q13) in various human cancers. In this study, we tested whether YEATS4 acts as a cancer-promoting gene through its activation/overexpression in gastric cancer (GC). We analyzed 5 GC cell lines and 135 primary tumor samples of GC, which were curatively resected in our hospital. Overexpression of the YEATS4 protein was frequently detected in GC cell lines (5/5 cell lines, 100%) and primary GC tumor tissues (32/135 cases, 23.7%). Knockdown of YEATS4 inhibited proliferation, migration and invasion of GC cells through NOTCH2 down-regulation in a TP53 mutation-independent manner, and induced apoptosis in wild-type TP53 GC cells. Moreover, knockdown of YEATS4 improved chemosensitivity for CDDP and L-OHP. Overexpression of YEATS4 protein significantly correlated with more aggressive lymphatic invasion, larger tumor size, deeper tumor depth, positive lymph node metastasis and recurrence. Patients with YEATS4-overexpressing tumors had a lower overall survival rate than those with non-expressing tumors. Multivariate analysis demonstrated that YEATS4 was independently associated with poor outcomes. These findings suggest that YEATS4 plays a pivotal role in tumor malignant potential through its overexpression and highlight its usefulness as a prognostic factor and potential therapeutic target in GC.

Entities:  

Keywords:  TP53; YEATS4; chemosensitivity; gastric cancer; overexpression

Year:  2018        PMID: 30662802      PMCID: PMC6325477     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  5 in total

1.  Structural Insights into Interaction Mechanisms of Alternative Piperazine-urea YEATS Domain Binders in MLLT1.

Authors:  Xiaomin Ni; David Heidenreich; Thomas Christott; James Bennett; Moses Moustakim; Paul E Brennan; Oleg Fedorov; Stefan Knapp; Apirat Chaikuad
Journal:  ACS Med Chem Lett       Date:  2019-11-25       Impact factor: 4.345

Review 2.  Multifaceted roles of YEATS domain-containing proteins and novel links to neurological diseases.

Authors:  Ranchana Yeewa; Pawita Chaiya; Salinee Jantrapirom; Vorasuk Shotelersuk; Luca Lo Piccolo
Journal:  Cell Mol Life Sci       Date:  2022-03-12       Impact factor: 9.261

3.  Overexpression of Tetraspanin31 contributes to malignant potential and poor outcomes in gastric cancer.

Authors:  Yusuke Takashima; Shuhei Komatsu; Takuma Ohashi; Jun Kiuchi; Hajime Kamiya; Hiroki Shimizu; Tomohiro Arita; Hirotaka Konishi; Atsushi Shiozaki; Takeshi Kubota; Kazuma Okamoto; Hitoshi Fujiwara; Hitoshi Tsuda; Eigo Otsuji
Journal:  Cancer Sci       Date:  2022-04-01       Impact factor: 6.518

4.  Development of potent dimeric inhibitors of GAS41 YEATS domain.

Authors:  Dymytrii Listunov; Brian M Linhares; EunGi Kim; Alyssa Winkler; Miranda L Simes; Sidney Weaver; Hyo Je Cho; Alexandrea Rizo; Sergey Zolov; Venkateshwar G Keshamouni; Jolanta Grembecka; Tomasz Cierpicki
Journal:  Cell Chem Biol       Date:  2021-07-21       Impact factor: 8.116

5.  Evaluation of the prognostic value of CBXs in gastric cancer patients.

Authors:  Mengya He; Limin Yue; Haiyan Wang; Feiyan Yu; Mingyang Yu; Peng Ni; Ke Zhang; Shuaiyin Chen; Guangcai Duan; Rongguang Zhang
Journal:  Sci Rep       Date:  2021-06-11       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.